PhRMA releases DTC comments

Share this article:
PhRMA's Office of Accountability released its second survey of comments received by companies regarding DTC ads, which showed concern among consumers and physicians about the clarity and creative choices of some ads.

PhRMA did not release the comments, but said most concerned the public health benefits of DTC ads and compliance with FDA regulations. Comments on the public health benefits of ads went both ways, with a number of negative comments concerning specific actors used in ads. Substantial numbers of commenters also expressed confusion about details of an ad or about risk information.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...